52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
15
Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.

Neogenesis
1
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.

Eisai
21
Modulators of leukotriene biosynthesis and receptor activation.

Abbott Laboratories
18
Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives.

Eisai
15
Synthesis of structural analogs of leukotriene B4 and their receptor binding activity.

Smithkline Beecham Pharmaceuticals
7
Synthesis and pharmacologic activity of hydroxyacetophenone-substituted benzophenone/xanthone leukotriene B4 receptor antagonists

TBA
23
Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.

Roche Research Center
15
The Role of Receptor Binding in Drug Discovery

TBA
3
New Leukotriene B
4 Receptor Antagonist: Leucettamine A and Related Imidazole Alkaloids from the Marine Sponge Leucetta microraphis

TBA
15
N-aryl cinnamides: A novel class of rigid and highly potent leukotriene B
4 receptor antagonists

TBA
1
3-Amino-1,2-benzisoxazoles: A new family of potent inhibitors of LTB
4 binding to the human neutrophils

TBA
4
Synthesis and pharmacological profile of new 1,3-disubstituted cyclohexanes as leukotriene B
4 receptor antagonists

TBA
10
Synthesis and in vitro profile of 7-substituted quinoline chromanols as novel, non-acidic LTB
4 antagonists

TBA
8
2-alkyl-4-ethyl-5-[6-methyl-6-(2H-tetrazol-5-yl)heptyloxy]phenol leukotriene B
4 receptor antagonists

TBA
11
Synthesis and pharmacological activity of SC-53228, a leukotriene B
4 receptor antagonist with high intrinsic potency and selectivity

TBA
5
Structural analogues of LY292728, a highly potent xanthone dicarboxylic acid leukotriene B
4 receptor antagonist: spatial positioning of the secondary acid group

TBA
6
Acid unit modifications of 1,2,4,5-substituted hydroxyacetophenones and the effect on
in vitro and
in vivo LTB
4 receptor antagonism

TBA
4
Ortho-alkoxyphenol leukotriene B4 receptor antagonists: effect of a chroman carboxylic acid.

TBA
8
Ortho-alkoxyphenol leukotriene B4 receptor antagonists

TBA
1
Enantioselective total synthesis and pharmacologic profile of 12-deoxy-12(S)-methyl leukotriene B
4
TBA
6
Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci.

Bristol Myers Squibb
22
Structure-activity relationships of indole cytosolic phospholipase A(2)alpha inhibitors: substrate mimetics.

Wyeth Research
6
Leukotriene B4 photoaffinity probes: design, synthesis and evaluation of new arylazide-1,3-disubstituted cyclohexanes.

Upresa-Cnrs 5074
27
Human disorders associated with inflammation and the evolving role of natural products to overcome.

University of Delhi
1
Carboxy-substituted cinnamides: a novel series of potent, orally active LTB4 receptor antagonists.

Novartis Pharmaceuticals
10
(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.

Smithkline Beecham Pharmaceuticals
3
Structure-activity relationships study of two series of leukotriene B4 antagonists: novel indolyl and naphthyl compounds substituted with a 2-[methyl(2-phenethyl)amino]-2-oxoethyl side chain.

RhôNe-Poulenc Rorer
3
A novel series of [2-[methyl(2-phenethyl)amino]-2-oxoethyl] benzene-containing leukotriene B4 antagonists: initial structure-activity relationships.

Rhone-Poulenc Rorer Central Research
6
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.

Smithkline Beecham Pharmaceuticals
7
Design, synthesis, and pharmacological evaluation of potent xanthone dicarboxylic acid leukotriene B4 receptor antagonists.

Eli Lilly
6
Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists.

Eli Lilly
13
Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.

Solvay Duphar
7
Synthesis and LTB4 receptor antagonist activities of the naturally occurring LTB4 receptor antagonist Leucettamine A and related analogues.

Smithkline Beecham Pharmaceuticals
32
Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships.

Smithkline Beecham Pharmaceuticals
17
Leukotriene B4 (LTB4) receptor antagonists: a series of (hydroxyphenyl)pyrazoles.

Eli Lilly
19
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.

Smithkline Beecham Pharmaceuticals
1
(+)-1-(3S,4R)-[3-(4-phenylbenzyl)-4-hydroxychroman-7-yl]cyclopentane carboxylic acid, a highly potent, selective leukotriene B4 antagonist with oral activity in the murine collagen-induced arthritis model.

Pfizer
20
Second-generation leukotriene B4 receptor antagonists related to SC-41930: heterocyclic replacement of the methyl ketone pharmacophore.

Searle Research and Development
5
Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.

Eli Lilly
1
Bis(sulfato)-cyclosiphonodictyol A, a new disulfated sesquiterpene-hydroquinone from a deep water collection of the Marine sponge Siphonodictyon coralliphagum.

Harbor Branch Oceanographic Institution
1
7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8- propyl-2H-1-benzopyran-2-carboxylic acid: an orally active selective leukotriene B4 receptor antagonist.

G.D. Searle And
2
Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain.

Eli Lilly
41
omega-[(4,6-Diphenyl-2-pyridyl)oxy]alkanoic acid derivatives: a new family of potent and orally active LTB4 antagonists.

Centre De Recherche De Vitry-Alfortville
22
omega-[(4-Phenyl-2-quinolyl)oxy]alkanoic acid derivatives: a new family of potent LTB4 antagonists.

Centre De Recherche De Vitry-Alfortville
4
4-[2-[Methyl(2-phenethyl)amino]-2-oxoethyl]-8-(phenylmethoxy)-2- naphthalenecarboxylic acid: a high affinity, competitive, orally active leukotriene B4 receptor antagonist.

Rhone-Poulenc Rorer Central Research
22
Omega-[(omega-arylalkyl)thienyl]alkanoic acids: from specific LTA4 hydrolase inhibitors to LTB4 receptor antagonists.

Centre De Recherche De Vitry-Alfortville
21
Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.

Merck Frosst Centre For Therapeutic Research
163
Sulfonamide compounds and uses as TNAP inhibitors

Sanford-Burnham Prebys Medical Discovery Institute
24
Prolyl hydroxylase inhibitors and methods of use

Akebia Therapeutics
116
Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors

Ziarco Pharma
6
Splicing factor SF3b as a target of the antitumor natural product pladienolide.

Eisai